List of Excipients in Branded Drug DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Endo USA Inc	dutasteride and tamsulosin hydrochloride	10370-280	AMMONIA
Endo USA Inc	dutasteride and tamsulosin hydrochloride	10370-280	BUTYLATED HYDROXYTOLUENE
Endo USA Inc	dutasteride and tamsulosin hydrochloride	10370-280	D&C YELLOW NO. 10
Endo USA Inc	dutasteride and tamsulosin hydrochloride	10370-280	ETHYLCELLULOSE
Endo USA Inc	dutasteride and tamsulosin hydrochloride	10370-280	FD&C BLUE NO. 1
Endo USA Inc	dutasteride and tamsulosin hydrochloride	10370-280	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE?

# Of NDCs	Excipient
2	ALCOHOL
4	AMMONIA
2	BUTYL ALCOHOL
5	BUTYLATED HYDROXYTOLUENE
1	CALCIUM STEARATE
3	CARRAGEENAN

Dutasteride and Tamsulosin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

The commercial opportunity for dutasteride/tamsulosin hydrochloride is concentrated in generic fixed-dose combinations, regional relaunches, manufacturing-cost reduction, and differentiated modified-release delivery. The reference product combines two technically different dosage forms in one hard capsule: a dutasteride liquid-filled soft gelatin capsule and tamsulosin hydrochloride modified-release pellets. That architecture creates formulation, bioequivalence, stability, and intellectual-property opportunities beyond simple tablet replication.

What is the reference formulation for dutasteride and tamsulosin hydrochloride?

The reference product, marketed in the United States as Jalyn, contains dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg in a once-daily hard capsule. It is approved for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. The combination reduces dihydrotestosterone through 5-alpha-reductase inhibition and improves urinary flow through alpha-1 adrenergic blockade [1].

Attribute	Dutasteride/tamsulosin combination
Reference brand	Jalyn
U.S. application	NDA 022460
Active ingredients	Dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg
Dosage form	Oral hard capsule
Dutasteride presentation	Liquid-filled soft gelatin capsule
Tamsulosin presentation	Modified-release pellets
Dosing	One capsule once daily
Primary indication	Symptomatic benign prostatic hyperplasia
Regulatory category	Small-molecule fixed-dose combination
Biosimilar pathway	Not applicable
Main competitive pathway	Abbreviated New Drug Application or equivalent national generic pathway

The formulation must preserve the distinct release behavior and chemical stability requirements of both active ingredients. Tamsulosin is intended for controlled release, while dutasteride is delivered from a liquid-filled softgel unit contained inside the capsule.

Which excipients are strategically important?

The highest-value excipient decisions relate to release control, solubilization, capsule integrity, moisture management, and manufacturing compatibility.

Dutasteride excipients

Dutasteride is a highly lipophilic, low-dose active pharmaceutical ingredient. A liquid-filled softgel approach can improve dose uniformity and reduce dependence on high-energy solid-state dispersion or extensive micronization.

Relevant excipient functions include:

Formulation function	Potential excipient class	Commercial rationale
Dutasteride solubilization	Medium-chain triglycerides, refined vegetable oils, esterified lipids	Supports a low-dose liquid fill
Wetting and dispersion	Surfactants and cosolvents	Reduces precipitation risk after capsule rupture
Softgel plasticization	Glycerol, sorbitol, or similar polyols	Controls shell flexibility
Shell formation	Gelatin or alternative film-forming polymers	Determines mechanical strength and dissolution
Opacity and light protection	Titanium dioxide or approved colorants	May improve product stability and identification
Oxidation control	Antioxidant systems where justified	Protects lipid vehicles and sensitive components
Moisture control	Low-moisture packaging and controlled shell water	Reduces migration and capsule brittleness

The main development risk is precipitation of dutasteride from the liquid vehicle after ingestion. A vehicle that dissolves dutasteride during manufacture may not maintain supersaturation in gastrointestinal fluid. Formulators should assess dispersion, precipitation, and supersaturation under biorelevant dissolution conditions rather than relying only on assay and content uniformity.

Tamsulosin modified-release pellet excipients

Tamsulosin hydrochloride is commonly formulated in modified-release pellets or beads. The pellet system separates drug layering from release-rate control and allows the manufacturer to tune dissolution without changing the overall capsule size.

Potential excipient layers include:

• Microcrystalline cellulose or sugar-based starter cores.
• Binders for drug layering.
• Povidone or related polymeric binders.
• Ethylcellulose or other water-insoluble polymers for sustained release.
• Methacrylate copolymers for pH-dependent or permeability-controlled release.
• Triethyl citrate or other plasticizers.
• Talc or anti-tacking agents.
• Colloidal silicon dioxide and processing aids.

The commercial target is a release profile that matches the reference product across multiple dissolution media. Tamsulosin pellet coatings must resist agglomeration, maintain coating uniformity, and prevent excessive early release. The product must also avoid alcohol-induced dose dumping or major release acceleration where relevant to the regulatory jurisdiction.

What excipient strategy is most suitable for a generic product?

A reference-matching strategy is generally lower risk than a fully redesigned dosage form.

Strategy 1: Replicate the dual-unit capsule

This approach places a dutasteride softgel and tamsulosin modified-release pellets in one hard capsule. It offers the closest route to the reference product and may simplify comparative dissolution and pharmacokinetic development.

Key advantages include:

• Direct alignment with the established clinical dosage form.
• Independent optimization of the two active ingredients.
• Lower risk of disturbing tamsulosin release kinetics.
• Potentially simpler justification of formulation differences.
• Use of existing softgel and pellet manufacturing platforms.

The main disadvantages are manufacturing complexity, higher capsule fill-cost, and the need to control interactions between the softgel shell, pellets, and outer capsule.

Strategy 2: Replace the dutasteride softgel with a solid dispersion or lipid-free system

A solid dosage form may reduce manufacturing complexity and improve capsule fill efficiency. Suitable approaches could include spray-dried dispersions, amorphous solid dispersions, adsorbed lipid systems, or micronized drug blends.

This strategy creates greater development risk because dutasteride has low aqueous solubility and the reference product uses a liquid-filled unit. A formulation change can affect apparent solubility, absorption, food effects, and pharmacokinetic comparability.

Strategy 3: Combine both actives in a multiparticulate capsule

A single capsule containing dutasteride granules or pellets and tamsulosin modified-release pellets can reduce component count. The release profiles must remain independent. The formulation must prevent dutasteride from altering tamsulosin coating performance or changing the microenvironmental pH within the capsule.

Strategy 4: Develop a tablet or bilayer tablet

A bilayer or matrix tablet may have lower manufacturing costs, but it is the most technically differentiated option. Tamsulosin requires controlled release, while dutasteride requires reliable solubilization. A tablet platform may also create more complex food-effect and dose-uniformity questions.

For a first generic launch, the dual-unit capsule is usually the most defensible technical platform. Tablet redesign is more attractive for markets where the reference capsule is difficult to source, where manufacturing scale justifies development expense, or where a company seeks a separate lifecycle-management position.

What formulation patents can protect the product?

Formulation-related patent positions can cover the delivery architecture rather than the active ingredients alone.

Potential claim categories include:

1. A hard capsule containing a dutasteride liquid-filled unit and tamsulosin modified-release pellets.
2. Specific lipid vehicles that maintain dutasteride solubility.
3. Pellet coating sequences and polymer ratios.
4. Dissolution profiles for tamsulosin hydrochloride.
5. Capsule-shell compositions that limit moisture migration.
6. Stabilized dutasteride compositions with defined impurity limits.
7. Manufacturing processes for drug layering, coating, drying, and capsule filling.
8. Packaging systems that protect the product from light or humidity.
9. Bioequivalent formulations with specified food-effect characteristics.
10. Fixed-dose combinations with defined pharmacokinetic relationships.

Patent strength depends on claim breadth, enablement, prosecution history, prior art, and whether a generic product can design around the claimed excipient ratios or manufacturing steps. Narrow claims directed only to a particular excipient concentration are more vulnerable to substitution. Claims tied to a functional dissolution profile, stability threshold, or integrated manufacturing process can be harder to avoid, although their enforceability depends on claim construction and proof.

When does dutasteride/tamsulosin lose exclusivity?

The principal active-ingredient patents for dutasteride and tamsulosin are no longer the central commercial barrier in the U.S. market. Tamsulosin has long been exposed to generic competition, and dutasteride generic products have also entered the market.

The relevant exclusivity analysis now centers on:

Exclusivity issue	Commercial effect
Active-ingredient patents	Limited barrier where expired or no longer enforceable
Fixed-dose combination patents	May delay or complicate a combination launch
Formulation patents	Can create product-specific design-around risk
Method-of-use patents	May affect labeling and Paragraph IV strategy
Regulatory exclusivity	Depends on application history and any granted pediatric or other exclusivity
Trade secrets	Can protect manufacturing know-how without blocking independent development
Regional rights	Patent and regulatory exposure varies by country

A current Orange Book review is required for product-specific conclusions on listed patents, certifications, and expiration dates. FDA identifies the Orange Book as the source for approved drug products, therapeutic equivalence information, and listed patent data [2].

What is the FDA regulatory status of the combination?

Jalyn was approved by FDA under NDA 022460. The product is a prescription fixed-dose combination for men with symptomatic benign prostatic hyperplasia and an enlarged prostate [1,3].

The central regulatory issues for a generic applicant are likely to include:

• Pharmaceutical equivalence of both active ingredients.
• Bioequivalence for the combination product.
• Comparable tamsulosin release characteristics.
• Dutasteride exposure from the selected liquid or solid vehicle.
• Food-effect comparability.
• Stability of the softgel, pellets, and outer capsule.
• Impurity and degradation-product control.
• Demonstration that the product is not subject to unacceptable dose dumping.
• Appropriate labeling and capsule-handling instructions.

Because dutasteride is associated with reproductive and handling precautions, packaging, labeling, and manufacturing controls have commercial importance. A product that simplifies handling without changing the approved dosage form could have a competitive advantage in institutional and pharmacy channels.

How many patents cover the product and what are the Paragraph IV risks?

The number of relevant patents cannot be inferred from the brand name alone. A complete assessment must separate:

• Patents listed against the fixed-dose combination NDA.
• Patents covering dutasteride.
• Patents covering tamsulosin.
• Formulation patents covering pellets, softgels, or capsule architecture.
• Method-of-use patents.
• Manufacturing and process patents not necessarily listed in the Orange Book.

A generic applicant filing an ANDA may submit a Paragraph IV certification against listed patents that it believes are invalid, unenforceable, or not infringed. The patent holder can then bring infringement litigation within the statutory window, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework, subject to court and regulatory developments [4].

For this product, the strongest Paragraph IV opportunities would likely involve:

• Non-infringement through a different dutasteride vehicle.
• Alternative tamsulosin coating polymers.
• Different pellet layering or manufacturing steps.
• Absence of infringement by a tablet or multiparticulate design.
• Invalidity arguments based on obviousness, anticipation, lack of written description, or lack of enablement.

A formulation that matches the reference dissolution profile while avoiding a claimed excipient combination is commercially valuable. The design-around must be established before ANDA filing because late reformulation can delay approval and trigger additional bioequivalence work.

Which companies are positioned to challenge the combination?

Competition is likely to come from several groups:

Large generic manufacturers

Companies with established softgel, pellet, and modified-release capabilities have the strongest technical position. Their advantages include existing equipment, analytical methods, scale, and experience with complex oral dosage forms.

Specialty generic companies

Smaller manufacturers may target countries where the combination is marketed but has fewer active formulation patents. They may use contract development and manufacturing organizations for softgel production or pellet coating.

Originator-affiliated suppliers

The originator’s manufacturing and licensing partners may retain commercial relevance through authorized generic supply, regional licensing, or contract manufacture.

Contract development and manufacturing organizations

Excipient and formulation specialists can monetize the opportunity through:

• Softgel development.
• Lipid formulation screening.
• Pellet coating development.
• Bioequivalence batches.
• Scale-up and commercial manufacture.
• Regulatory documentation.
• Stability and packaging programs.

What commercial opportunities exist beyond a standard generic?

Authorized generic or regional license

A licensee can use an existing formulation and manufacturing package to enter markets where the brand has limited distribution or where local registration is needed. This model reduces formulation risk but may produce lower margins.

Complex generic fixed-dose combination

A company that develops a robust dual-unit capsule can create a barrier against manufacturers that only produce simple tablets or single-ingredient products. The combination may support premium pricing over separate generic prescriptions in selected markets.

Hospital and institutional packaging

Blister configurations that protect the capsule from humidity and reduce handling exposure may appeal to institutional pharmacies. Unit-dose packaging can also support adherence programs.

Lower-cost formulation redesign

Replacing the softgel with a stable solid or lipid-adsorbed system could reduce unit cost, improve automated filling, and simplify global supply. The commercial value depends on whether the redesigned product can achieve approval without extensive clinical bridging.

Combination adherence positioning

A fixed-dose capsule reduces the number of daily dosage units from two to one. That benefit can support pharmacy substitution, payer discussions, and adherence-focused commercialization, although any superiority claim would require appropriate evidence.

Emerging-market formulations

In countries with high out-of-pocket drug spending, a lower-cost combination may compete effectively against branded dutasteride and tamsulosin products. Regional opportunities are strongest where the combination is approved but generic penetration remains low.

How does the product compare with separate dutasteride and tamsulosin?

Commercial factor	Fixed-dose combination	Separate products
Daily pill burden	One capsule	Two dosage units
Dose flexibility	Limited	Each active can be adjusted independently
Manufacturing	More complex	Simpler individual products
Bioequivalence	Combination-specific	Established separately
Adherence proposition	Stronger	Weaker unless co-packaged
Inventory	One combined SKU	Two SKUs
Formulation risk	Higher	Lower
Pricing flexibility	Potential combination premium	Greater substitution pressure
Patient selection	Requires both therapies	Allows independent titration

The fixed-dose product is most attractive for patients who already require both mechanisms and have stable doses. Separate products remain preferable when dose adjustment, intolerance, or treatment sequencing is important.

What manufacturing and IP barriers matter most?

The leading barriers are not raw-material availability. They are process control and performance reproducibility.

Key barriers include:

• Uniform dutasteride distribution in a low-dose liquid fill.
• Prevention of softgel leakage or shell embrittlement.
• Consistent tamsulosin pellet coating thickness.
• Control of pellet friability and agglomeration.
• Prevention of interaction between liquid-filled and dry components.
• Matching reference dissolution across pH conditions.
• Maintaining stability under high humidity.
• Obtaining reliable commercial-scale bioequivalence.
• Avoiding formulation and process patent claims.
• Establishing qualified suppliers for specialized coating polymers and capsule materials.

Excipient suppliers can capture value through proprietary grades, technical support, and regulatory documentation. The strongest positions are likely in modified-release polymers, pellet-coating systems, lipid vehicles, capsule-shell technology, and moisture-barrier packaging.

What is the revenue exposure and generic launch risk?

Revenue exposure depends on the size of the branded combination market, the proportion of patients receiving both active ingredients, and the extent of generic substitution. A generic launch can reduce brand revenue rapidly if the product is dispensed through channels with high automatic substitution.

Launch risk can be segmented as follows:

Risk	Assessment
Active-ingredient availability	Low
Simple API sourcing	Low to moderate
Dual-unit formulation	Moderate to high
Modified-release bioequivalence	Moderate to high
Softgel manufacturing	Moderate
Formulation patent exposure	Product-specific
Regulatory complexity	Moderate
Biosimilar competition	None
Substitution pressure after approval	High

The most attractive commercial plan is a formulation that preserves the reference performance while reducing softgel and pellet manufacturing cost. A product with a credible design-around position, strong humidity stability, and scalable capsule-filling process can compete even where several generic manufacturers have access to the APIs.

Key Takeaways

• Dutasteride/tamsulosin hydrochloride is a complex oral fixed-dose combination, not a conventional immediate-release capsule.
• The reference architecture uses a dutasteride liquid-filled softgel and tamsulosin modified-release pellets inside a hard capsule.
• The primary excipient opportunities are lipid solubilization, modified-release coating, capsule-shell control, moisture protection, and manufacturing simplification.
• A dual-unit capsule is the lowest-risk generic development strategy.
• Solid dispersions, lipid-adsorbed systems, multiparticulates, and bilayer tablets offer lifecycle and cost-reduction opportunities but carry higher bioequivalence risk.
• U.S. competition is driven primarily by formulation, process, and combination-product patent issues rather than basic API exclusivity.
• Biosimilar risk is not relevant because both actives are small molecules.
• The strongest commercial positions are likely to come from scalable pellet coating, stable dutasteride liquid or lipid systems, and differentiated packaging.
• Paragraph IV strategy depends on a current Orange Book and patent-family review for NDA 022460 and related formulation patents.
• Generic launch risk is moderate to high because the product must reproduce two different release technologies in one dosage form.

FAQs About Dutasteride and Tamsulosin Excipient Strategy

Can dutasteride and tamsulosin be formulated in one immediate-release tablet?

Technically, a single immediate-release tablet is possible, but it would not automatically reproduce the reference product. Tamsulosin release control, dutasteride solubilization, food effects, and bioequivalence would require separate development and regulatory justification.

Which excipient is best for solubilizing dutasteride?

No single excipient is universally optimal. Lipid vehicles such as medium-chain triglycerides or other pharmaceutical oils are logical starting points, but selection must be based on solubility, precipitation, stability, capsule compatibility, and in vitro-in vivo performance.

Does tamsulosin require a modified-release polymer?

A generic product must reproduce the reference release behavior. Modified-release polymers, coating layers, pellet geometry, and manufacturing conditions can all contribute to that profile. The specific polymer system is a development choice subject to bioequivalence and patent analysis.

Is a dutasteride/tamsulosin product a biosimilar?

No. Dutasteride and tamsulosin hydrochloride are small-molecule active ingredients. Follow-on products are generally regulated as generics or equivalent national applications, not biosimilars.

Can a manufacturer avoid combination-product patents by selling two separate capsules?

Selling separate dutasteride and tamsulosin products may avoid claims limited to a fixed-dose combination dosage form, but it does not eliminate possible claims covering the individual formulations, methods of use, or manufacturing processes. Patent scope must be assessed claim by claim.

References

1. U.S. Food and Drug Administration. (2010). Jalyn (dutasteride and tamsulosin hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Jalyn NDA 022460.
4. U.S. Food and Drug Administration. (2015). ANDA submissions: Refuse-to-receive standards. FDA guidance and Hatch-Waxman certification framework.